News India Times
Buisness

From June 1, cough syrup exporters must conduct product testing at government laboratories

Share

From June 1, cough syrup exporters will need to test their goods at certain government labs before obtaining approval for outbound shipments.
Following worldwide concerns over the quality of cough syrups exported by Indian companies, the direction has been changed.
The Directorate General of Foreign Trade (DGFT) said on Monday that, starting on June 1, 2023, “the export of cough syrup will be authorized to be exported subject to export samples being tested and presentation of certificate of analysis provided by any of the labs…
The NABL (National Accreditation Board for Testing and Calibration Laboratories) accredited drug testing labs of state governments are also listed among the specified central government labs, along with the Indian Pharmacopoeia Commission, regional drug testing lab (RDTL – Chandigarh), central drugs lab (CDL – Kolkata), central drug testing lab (CDTL – Chennai Hyderabad, Mumbai), and RDTL (Guwahati).
An official went on to explain that the federal government has chosen to start a process of a pre-quality inspection of the cough syrup formulations being exported in order to reaffirm India's commitment to guaranteeing the quality of diverse pharmaceutical goods produced from India.
The official stated, “The finished goods (in this case, cough syrup) are to be tested at laboratories before being permitted for export,” and that MoHFW would work with the state governments and the exporters to ensure smooth implementation of this notification. The official also added that necessary steps are being taken to ensure the smooth implementation of this testing requirement.
Global Pharma Healthcare, located in Tamil Nadu, recalled the whole batch of eye drops in February. Earlier, cough medicines produced in India were thought to have contributed to the deaths of 66 and 18 kids in the Gambia and Uzbekistan, respectively, last year.
In 2022–2023, India exported cough syrups worth US$17.6 billion, up from US$17 billion in 2021–2022 period.
The LMIC (low and medium income countries) and highly developed nations alike purchase medical items from the Indian pharmaceutical sector, which is a significant global producer and supplier of pharmaceuticals.
India is the world's leading supplier of generic medications, meeting more than 50% of the demand for different vaccines internationally, around 40% of generic drug demand in the US, and over 25% of total medicine demand in the UK.
India is the third-largest pharmaceutical producer in the world by volume and the fourteenth-largest by value.
There are around 10,500 production facilities and a network of 3,000 pharmaceutical businesses in this sector. It makes it easier for high-quality, reasonably priced, and easily accessible pharmaceuticals to be supplied and made available globally. India has a significant place in the world's pharmaceutical industry.
Currently, Indian pharmaceutical companies provide over 80% of the antiretroviral medications used to treat AIDS worldwide.

Share

Related posts

Pragati Maidan in Delhi is preparing for Franchise India 2023 to draw businesspeople from around the country

cradmin

Bridging the gap: a tighter match between industry expectations and cybersecurity education

cradmin

Bank of Baroda intends to issue bonds to raise Rs 10,000 crore

cradmin